Pituitary adenomas (PAs) are neoplasms derived from the endocrine cells of the anterior
pituitary gland. Most frequently, they are benign tumors, but may sometimes display an …

After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …

Pituitary neuroendocrine tumor (PitNET) is one of the most common intracranial tumors. Due
to its extensive tumor heterogeneity and the lack of high-quality tissues for biomarker …

Objective After temozolomide failure, no evidence-based treatment is available for pituitary
carcinomas (PCs) and aggressive pituitary tumors (APTs). To date, only 12 cases treated …

Pituitary tumors are rare neoplasms, with a heterogeneous biological and clinical behavior,
due to their clinical course, local invasive growth, resistance to conventional therapies and …

The tumor microenvironment (TME), the complex environment in which tumors develop, has
been increasingly targeted for cancer treatment in recent years. Aggressive pituitary tumors …

Simple Summary Few therapies are available for patients with aggressive or metastatic
pituitary neuroendocrine tumours (PitNETs). Peptide receptor radionuclide therapy (PRRT) …

The pituitary tumour microenvironment encompasses a spectrum of non-tumoural cells, such
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …

Prolactinomas are the most common functional pituitary tumors, accounting for 40% of all
pituitary adenomas. Medical treatment with dopamine agonists (DA), mainly cabergoline, is …

Abstract Background Pituitary neuroendocrine tumors (PitNETs) are common gland
neoplasms demonstrating distinctive transcription factors. Although the role of immune cells …